Biotech entity
Every one of those 1 sits in a single category, pharma. EVERTEC is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. Frontdoor appears in 1 tracked Biotech story from February 25, 2026.
Last mentioned: Mar 11, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. EVERTEC is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 4 original sources each. Frontdoor appears in 1 tracked Biotech story from February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Frontdoor. Shared-story counts are live from our verified record — not editorial picks.
As the Q4 2025 earnings cycle concludes, investors are prioritizing results from Natera and Lantheus to gauge the health of the liquid biopsy and radiopharmaceutical markets. These reports will provide critical data on the adoption of minimal residual disease (MRD) testing and the competitive dynamics of prostate cancer imaging.
Frontdoor is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
